.World Health Institution. Excessive weight and obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Condition Danger Aspect Partnership. Worldwide patterns in underweight as well as being overweight coming from 1990 to 2022: a pooled evaluation of 3663 population-representative studies along with 222 thousand youngsters, teens, and also adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.International Problem Condition Partners. Global, regional, and nationwide worry of diabetes from 1990 to 2021, along with estimates of prevalence to 2050: a systematic evaluation for the Global Worry of Health Condition Research Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Kidney Day Steerage Committee. Weight problems and also kidney condition: concealed outcomes of the wide-ranging. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
An organized testimonial as well as meta-analysis recommends being overweight predicts beginning of persistent renal health condition in the overall population. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Weight problems as well as persistent kidney ailment.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Hall, J. E., will Carmo, J. M., da Silva, A.
A., Wang, Z. & Hall, M. E.
Excessive weight, kidney dysfunction and hypertension: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kidney Illness: Improving Global End Results CKD Work Group.
KDIGO 2024 Scientific Process Standard for the evaluation and control of severe renal condition. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Renal Health Condition: Improving Global Results Diabetes Mellitus The Office Group. KDIGO 2022 Clinical Process Tip for diabetes mellitus control in chronic kidney illness. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et al.
Very early change in albuminuria with canagliflozin predicts kidney as well as cardiovascular end results: a message hoc review coming from the support test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, an aim at for renoprotection in patients with type 2 diabetic person nephropathy: sessions from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et cetera. Is a decrease in albuminuria related to kidney and also heart security?
A post hoc evaluation of the elevation test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a testimonial of their kidney as well as heart defense. Am.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 and also the kidney: coming from anatomy to pharmacology and also outcomes in diabetes mellitus.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and also cardio end results in patients along with type 2 diabetic issues. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et al. Semaglutide and heart results in excessive weight without diabetes. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et al.
Effects of semaglutide on chronic kidney condition in clients with kind 2 diabetes. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Lasting kidney end results of semaglutide in obesity and cardiovascular disease in the SELECT test. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of semaglutide on albuminuria as well as kidney functionality in people with obese or even being overweight with or without kind 2 diabetic issues: prolegomenous review coming from the STEP 1, 2, and also 3 trials.
Diabetes Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Medicine Man, A. M.
et cetera. Effect of the glucagon-like peptide-1 receptor agonists semaglutide as well as liraglutide on renal results in patients with type 2 diabetes mellitus: pooled evaluation of SUSTAIN 6 and LEADER. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et al.
Result of semaglutide on renal functionality across various amounts of guideline HbA1c, high blood pressure, body system weight and also albuminuria in SUSTAIN 6 and trailblazer 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus blood insulin glargine in people with style 2 diabetes and also moderate-to-severe persistent kidney illness (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Mellitus Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Improvement in albuminuria as a surrogate endpoint for progress of renal health condition: a meta-analysis of treatment effects in randomised scientific trials. Lancet Diabetic Issues Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Results of semaglutide with as well as without associated with SGLT2 prevention make use of in individuals along with style 2 diabetes and severe renal disease in the circulation trial. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and also safety and security results along with GLP-1 receptor agonists alone and also in mixture along with SGLT2 inhibitors in kind 2 diabetes mellitus: a step-by-step customer review and also meta-analysis.
Flow https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Efficiency as well as protection of SGLT2 preventions with and without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised regulated trials. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Results of tirzepatide versus the hormone insulin glargine on renal end results in type 2 diabetic issues in the SURPASS-4 trial: post-hoc study of an open-label, randomised, phase 3 trial.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et al. Physical body weight and also eGFR during the course of dulaglutide therapy in style 2 diabetes and also moderate-to-severe severe kidney disease (AWARD-7).
Diabetes mellitus Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J. L.
et al. Results of tirzepatide versus insulin glargine on cystatin c-based renal functionality: a SURPASS-4 message hoc analysis. Diabetic issues Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Diabetes Treatment (American Diabetic issues Association, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et cetera. Effects of bariatric surgical treatment on renal function in obese patients: a systematic analysis as well as meta evaluation.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The effects of bariatric surgical operation on kidney outcomes: an organized analysis and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The gauged glomerular filtration cost (mGFR) prior to and also 6 months after bariatric surgical procedure: a captain research. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et cetera. Adiponectin minimizes glomerular endothelial glycocalyx disruption and repairs glomerular obstacle feature in a mouse style of style 2 diabetes. Diabetic issues 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration related to diabetic issues mellitus as well as weight problems in individual illness. Realm J.
Diabetic Issues 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Gauging albuminuria in people with obesity: risks of the urinary albumin-creatinine ratio. Kidney Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in adults with obese or being overweight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et cetera. An even more exact approach to determine glomerular purification rate coming from product creatinine: a brand new prediction formula.
Alteration of Diet Regimen in Renal Disease Study Group. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS strategy for iohexol decision in individual EDTA as well as lithium-heparin blood, individual urine and in goat- and swine EDTA plasma. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et al.
Efficiency as well as safety of aldosterone synthase hangup along with and also without empagliflozin for severe kidney illness: a randomised, controlled, stage 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et al. Effectiveness of an unfamiliar prevention of general adhesion protein-1 in reducing albuminuria in individuals along with diabetic person renal ailment (CD): a randomised, placebo-controlled, period 2 test. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in combo with dapagliflozin compared with dapagliflozin in individuals with severe renal condition (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, medical trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Impact of avenciguat on albuminuria in individuals with CKD: two randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in patients along with IgA nephropathy: a prespecified meantime evaluation due to a randomised, double-blind, active-controlled medical test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.